General Information of Drug (ID: DM3ZN6Y)

Drug Name
FPA-008 Drug Info
Indication
Disease Entry ICD 11 Status REF
Autoimmune diabetes 5A10 Phase 1/2 [1]
Pigmented villonodular synovitis FA27.1 Phase 1 [2]
Tenosynovial giant cell tumour 2F7B Phase 1 [2]
Cross-matching ID
TTD Drug ID
DM3ZN6Y

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Approved Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
ARRY-382 DM0VGDC Solid tumour/cancer 2A00-2F9Z Phase 2 [4]
RG7155 DM8JMNL Solid tumour/cancer 2A00-2F9Z Phase 2 [5]
MCS-110 DM0CL4I Bone metastases 2D50 Phase 2 [6]
JNJ-40346527 DM219SF Hodgkin lymphoma 2B30 Phase 2 [7]
PD-360324 DM6F5EV Rheumatoid arthritis FA20 Phase 2 [8]
AMG 820 DMB6Q19 Solid tumour/cancer 2A00-2F9Z Phase 1 [6]
IMC-CS4 DMUYN26 Solid tumour/cancer 2A00-2F9Z Phase 1 [6]
⏷ Show the Full List of 7 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Pexidartinib DMS2J0Z Tenosynovial giant cell tumour 2F7B Approved [9]
Sulfatinib DMPOTM4 Neuroendocrine cancer 2B72.1 Phase 3 [10]
ARRY-382 DM0VGDC Solid tumour/cancer 2A00-2F9Z Phase 2 [10]
BLZ-945 DMG1LVA Amyotrophic lateral sclerosis 8B60.0 Phase 2 [10]
Cabiralizumab DMGE058 Pancreatic cancer 2C10 Phase 2 [11]
AMB-05X DM958C5 Idiopathic pulmonary fibrosis CB03.4 Phase 2 [12]
DCC-3014 DMHW289 Solid tumour/cancer 2A00-2F9Z Phase 1/2 [10]
DCC-3014 DMHW289 Solid tumour/cancer 2A00-2F9Z Phase 1/2 [13]
PLX7486 DM0IVGU Pancreatic cancer 2C10 Phase 1 [10]
TPX-0022 DMC2IJN Solid tumour/cancer 2A00-2F9Z Phase 1 [14]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Colony stimulating factor-1 receptor (CSF-1R) TT731LW E9PEK4_HUMAN Modulator [3]
Macrophage colony-stimulating factor 1 receptor (CSF1R) TT7MRDV CSF1R_HUMAN Not Available [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800039179)
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Company report (Five Prime Therapeutics)
4 Company report (Array)
5 Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell. 2014 Jun 16;25(6):846-59.
6 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
7 An Open-Label, Multicenter, Phase I/II Study of JNJ-40346527, a CSF-1R Inhibitor, in Patients with Relapsed or Refractory Hodgkin Lymphoma. Clin Cancer Res. 2015 Apr 15;21(8):1843-50.
8 Monoclonal antibody against macrophage colony-stimulating factor suppresses circulating monocytes and tissue macrophage function but does not alter cell infiltration/activation in cutaneous lesions or clinical outcomes in patients with cutaneous lupus erythematosus.Clin Exp Immunol.2016 Feb;183(2):258-70.
9 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
10 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
11 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
12 Clinical pipeline report, company report or official report of AmMax Bio
13 Clinical pipeline report, company report or official report of Deciphera Pharmaceuticals.
14 Clinical pipeline report, company report or official report of Turning Point Therapeutics.